📰 2 sources covering this story

FDA advisory panel backed Replimune's twice-rejected melanoma treatment in 10-3 vote

First covered 1 days ago · latest take 1 hrs ago. Compare how each outlet is covering it — and rate the sources you trust.

FDA advisory panel backed Replimune's twice-rejected melanoma treatment in 10-3 vote
Quartz
Quartz1 hrs ago
FDA advisory panel backed Replimune's twice-rejected melanoma treatment in 10-3 vote
The vote raises the chance the FDA will approve RP1, an engineered viral immunotherapy, ahead of an Aug. 2 decision deadline
STAT News
STAT News🏁 first to report1 days ago
STAT+: Tracking the FDA expert review of Replimune’s melanoma treatment
STAT is live-blogging a meeting of FDA experts to review Replimune’s experimental melanoma drug, RP1.
Top rated outlets
Outlets are ranked once they have 3+ community ratings — be one of the first to rate.
🏆 Most trusted sources 2026 →
Scores come entirely from reader ratings — rate the sources you read to shape them. How it works →